Surgery Partners Sets 2026 Guidance, Launches $200 Million Share Repurchase Amid Mixed 2025 Results
Resilient Revenue Growth but Margin Pressures Evident in 2025
Surgery Partners, Inc. (NASDAQ:SGRY) reported its fourth quarter and full-year 2025 results, highlighting revenue growth and strategic optimism even as profitability faced obstacles. Full-year revenue grew by 6.2% to $3.31 billion, while same-facility revenues increased by 4.9%. Notably, same-facility cases in 2025 rose 3.4%, even as overall surgical cases increased by only 2%, indicating continued demand at the company’s core facilities.
Despite these positives, margin pressures weighed on the bottom line. Adjusted EBITDA increased 3.5% year over year to $526.2 million, but EBITDA margin slipped to 15.9% from 16.3% last year. A net loss attributable to the company of $77.9 million for 2025 was recorded, though this marked an improvement over the $168.1 million net loss in 2024.
| Metric | Q4 2025 | Q4 2024 | FY 2025 | FY 2024 |
|---|---|---|---|---|
| Revenue ($M) | 885.0 | 864.4 | 3,308.7 | 3,114.3 |
| Adjusted EBITDA ($M) | 156.9 | 163.8 | 526.2 | 508.2 |
| EBITDA Margin (%) | 17.7 | 18.9 | 15.9 | 16.3 |
| Net Loss Attributable ($M) | -15.0 | -108.5 | -77.9 | -168.1 |
Cautious Optimism Underpins 2026 Guidance and Margin Improvement Strategy
Looking ahead, Surgery Partners set its 2026 guidance with at least $530 million in Adjusted EBITDA and revenues projected in the range of $3.35 to $3.45 billion—representing a measured but positive outlook. Management signaled a focus on organic growth, higher-acuity procedures, and operational improvements to address recent margin pressure. The company’s net debt to EBITDA ended 2025 at approximately 4.3x, with liquidity supported by $239.9 million in cash and nearly $693 million available under its revolving credit facility.
CEO Eric Evans highlighted ongoing demand for surgical services and strategic initiatives to position the company for growth, while CFO Dave Doherty noted actions to operationally "tighten execution." The company is expected to balance its ambitions by managing overhead and portfolio optimization while riding structural tailwinds in the ambulatory surgery center (ASC) sector.
Shareholder Returns Take Center Stage with $200 Million Buyback
In a move likely to be well received by investors, Surgery Partners’ Board authorized a $200 million common stock share repurchase program. This signals confidence in the company’s long-term value and provides a buffer against recent share price volatility. Share buybacks can help offset dilution, support the stock price, and return value directly to shareholders during periods of operational transition.
Key Operational Trends: Case Growth and Profitability Dynamics
While full-year surgical cases grew 2% to 669,732, the efficiency and pricing power at established facilities stood out. Revenue per case increased 4.2% for the quarter year-over-year and rose to $4,940 for the full year. Same-facility cases rose 3.4%, underpinning organic growth strategy momentum. However, margin contraction—Adjusted EBITDA margin dipped to 15.9% for 2025—will remain an area for close monitoring as management shifts focus to higher-value procedures and expense controls.
| Key Operating Metrics | 2025 | 2024 |
|---|---|---|
| Total surgical cases | 669,732 | 656,732 |
| Same-facility case growth (%) | 3.4 | N/A |
| Revenue per case | $4,940 | $4,742 |
Takeaway: What to Watch Moving Forward
Surgery Partners’ 2025 performance underscores the challenge of navigating near-term margin pressures while delivering revenue and case growth at its core centers. The new $200 million buyback program adds confidence for shareholders, and the company’s 2026 guidance suggests steady progress with a measured approach. For investors and sector watchers, the key questions remain: Can SGRY improve margins amid ongoing wage and cost pressures, and will strategic shifts into higher-acuity procedures pay off?
The upcoming conference call and ongoing operational metrics will shed light on whether the company’s optimism for 2026 is warranted. Until then, Surgery Partners stands at a pivotal moment—balancing disciplined execution with ambitions to lead in the rapidly evolving surgical services sector.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI